Third Pole Therapeutics anticipates FDA clearance end of 2021 to treat newborn respiratory failure
Third Pole Therapeutics CEO Bill Athenson sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. Click to View Article